Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Dow
Merck
McKesson
Harvard Business School

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

VISTIDE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Vistide, and when can generic versions of Vistide launch?

Vistide is a drug marketed by Gilead Sciences Inc and is included in one NDA.

The generic ingredient in VISTIDE is cidofovir. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cidofovir profile page.

US ANDA Litigation and Generic Entry Outlook for Vistide

A generic version of VISTIDE was launched as cidofovir by MYLAN INSTITUTIONAL on December 13th, 2019.

Summary for VISTIDE
Drug patent expirations by year for VISTIDE
Recent Clinical Trials for VISTIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of PennsylvaniaPhase 2
National Cancer Institute, FrancePhase 1
Gustave Roussy, Cancer Campus, Grand ParisPhase 1

See all VISTIDE clinical trials

Synonyms for VISTIDE
({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
(2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine
(S)-(((1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonic acid
(S)-(3-(4-amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid
(s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine
(S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine
(S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid
(S)-HPMPC
(S)-HPMPC; Cidovir
[(1S)-1-[(4-amino-2-oxo-pyrimidin-1-yl)methyl]-2-hydroxy-ethoxy]methylphosphonic acid
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
[1-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-propan-2-yl]oxymethylphosphonic acid
1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate
1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine
113852-37-2
120362-37-0 (hydrochloride salt)
394C661
768M1V522C
AB01566823_01
AC-1666
AC1L1TLB
AC1Q6C68
AKOS005145721
AKOS015854828
AN-14714
AN-8255
API0002008
BC209905
BCP03734
BCP0726000147
BCP9000528
BDBM31915
BG0579
C8H14N3O6P
CAS-113852-37-2
CC0162
CDV
CHEBI:3696
CHEMBL152
Cidofovir
Cidofovir (anhydrous)
Cidofovir (Vistide)
Cidofovir [INN]
Cidofovir anhydrous
Cidofovir gel
Cidofovir, anhydrous
Cidofovir,Vistide
Cidofovir(anhydrous)
Cidofovir(Vistide)
Cidofovirum
CS-1669
DB00369
DSSTox_CID_23734
DSSTox_GSID_43734
DSSTox_RID_80069
DTXSID3043734
EBD21562
Forvade
Forvade (TM)
FT-0623818
GS 0504
GS 504
GS-0504
GS-504
GS-6438
GS504
HPMPC
HSDB 7115
HY-17438
J-502695
KB-302539
KS-00000XN7
L8P
LS-106432
MFCD17215968
MLS003915629
NCGC00184994-01
NCGC00184994-02
NCGC00184994-03
NSC-742135
NSC742135
Phosphonic acid, ((2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, (S)-
Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-
Phosphonic acid,[[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-
s1516
SCHEMBL3948
SMR002544687
SR-01000931969
SR-01000931969-2
Tox21_112994
UNII-768M1V522C
VWFCHDSQECPREK-LURJTMIESA-N
ZINC1530600

US Patents and Regulatory Information for VISTIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc VISTIDE cidofovir INJECTABLE;INJECTION 020638-001 Jun 26, 1996 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Merck
AstraZeneca
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.